MX2023005678A - Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas. - Google Patents
Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas.Info
- Publication number
- MX2023005678A MX2023005678A MX2023005678A MX2023005678A MX2023005678A MX 2023005678 A MX2023005678 A MX 2023005678A MX 2023005678 A MX2023005678 A MX 2023005678A MX 2023005678 A MX2023005678 A MX 2023005678A MX 2023005678 A MX2023005678 A MX 2023005678A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- cyclopentathiophene
- factor receptor
- activating factor
- platelet activating
- Prior art date
Links
- ADEGUPDGFKUYII-UHFFFAOYSA-N 2H-cyclopenta[b]thiophene-2-carboxamide Chemical class S1C=2C(=CC1C(=O)N)C=CC=2 ADEGUPDGFKUYII-UHFFFAOYSA-N 0.000 title abstract 2
- 108700023400 Platelet-activating factor receptors Proteins 0.000 title abstract 2
- 102000030769 platelet activating factor receptor Human genes 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Ciclopentatiofen carboxamidas de la Fórmula (I.0) (ver Fórmula) en donde R1, R2, R3, R4 y n son como se definen en la descripción y las reivindicaciones, y las sales farmacéuticamente aceptables de este pueden usarse en métodos para el tratamiento de enfermedades que pueden estar influenciadas por antagonizar la actividad mediada por el receptor del factor de activación de plaquetas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207719 | 2020-11-16 | ||
| PCT/EP2021/081459 WO2022101377A1 (en) | 2020-11-16 | 2021-11-12 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005678A true MX2023005678A (es) | 2023-05-26 |
Family
ID=73543025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005678A MX2023005678A (es) | 2020-11-16 | 2021-11-12 | Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11766443B2 (es) |
| EP (1) | EP4244229A1 (es) |
| JP (1) | JP7465368B2 (es) |
| KR (1) | KR20230109692A (es) |
| CN (2) | CN117624188A (es) |
| AR (1) | AR124070A1 (es) |
| AU (1) | AU2021379248A1 (es) |
| CA (1) | CA3200710A1 (es) |
| CL (1) | CL2023001361A1 (es) |
| CO (1) | CO2023005894A2 (es) |
| CR (1) | CR20230211A (es) |
| DO (1) | DOP2023000090A (es) |
| EC (1) | ECSP23036210A (es) |
| IL (1) | IL302769A (es) |
| MX (1) | MX2023005678A (es) |
| TW (1) | TW202237620A (es) |
| WO (1) | WO2022101377A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3502392A1 (de) | 1985-01-25 | 1986-07-31 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen |
| PH30676A (en) | 1986-07-22 | 1997-09-16 | Boehringer Ingelhein Kg | Hetrazepine compounds which have useful pharmaceutical utility |
| DE3909012A1 (de) | 1989-03-18 | 1990-09-20 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen |
| DE4010528A1 (de) | 1990-04-02 | 1991-10-17 | Boehringer Ingelheim Kg | Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine |
| DE4132763A1 (de) | 1991-10-02 | 1993-04-08 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| US20050032713A1 (en) * | 2002-03-27 | 2005-02-10 | Wurtman Richard J. | Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents |
| WO2008063667A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterotricyclic metalloprotease inhibitors |
-
2021
- 2021-11-12 CN CN202311341729.0A patent/CN117624188A/zh active Pending
- 2021-11-12 MX MX2023005678A patent/MX2023005678A/es unknown
- 2021-11-12 JP JP2022562298A patent/JP7465368B2/ja active Active
- 2021-11-12 CN CN202180076849.5A patent/CN116745300A/zh active Pending
- 2021-11-12 IL IL302769A patent/IL302769A/en unknown
- 2021-11-12 KR KR1020237020295A patent/KR20230109692A/ko unknown
- 2021-11-12 CR CR20230211A patent/CR20230211A/es unknown
- 2021-11-12 EP EP21806745.2A patent/EP4244229A1/en active Pending
- 2021-11-12 CA CA3200710A patent/CA3200710A1/en active Pending
- 2021-11-12 US US17/524,759 patent/US11766443B2/en active Active
- 2021-11-12 AU AU2021379248A patent/AU2021379248A1/en active Pending
- 2021-11-12 WO PCT/EP2021/081459 patent/WO2022101377A1/en active Application Filing
- 2021-11-15 TW TW110142333A patent/TW202237620A/zh unknown
- 2021-11-15 AR ARP210103159A patent/AR124070A1/es unknown
-
2023
- 2023-05-08 CO CONC2023/0005894A patent/CO2023005894A2/es unknown
- 2023-05-11 DO DO2023000090A patent/DOP2023000090A/es unknown
- 2023-05-11 CL CL2023001361A patent/CL2023001361A1/es unknown
- 2023-05-17 EC ECSENADI202336210A patent/ECSP23036210A/es unknown
- 2023-07-14 US US18/221,936 patent/US20230355638A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR124070A1 (es) | 2023-02-08 |
| US20220160725A1 (en) | 2022-05-26 |
| ECSP23036210A (es) | 2023-06-30 |
| CN117624188A (zh) | 2024-03-01 |
| IL302769A (en) | 2023-07-01 |
| JP2023521200A (ja) | 2023-05-23 |
| KR20230109692A (ko) | 2023-07-20 |
| DOP2023000090A (es) | 2023-06-15 |
| AU2021379248A1 (en) | 2023-06-22 |
| TW202237620A (zh) | 2022-10-01 |
| WO2022101377A1 (en) | 2022-05-19 |
| CA3200710A1 (en) | 2022-05-19 |
| CN116745300A (zh) | 2023-09-12 |
| JP7465368B2 (ja) | 2024-04-10 |
| US20230355638A1 (en) | 2023-11-09 |
| CR20230211A (es) | 2023-07-13 |
| EP4244229A1 (en) | 2023-09-20 |
| US11766443B2 (en) | 2023-09-26 |
| CO2023005894A2 (es) | 2023-05-29 |
| CL2023001361A1 (es) | 2023-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20051265L (no) | Anvendelse av og noen nye imidazopyridiner | |
| MX2020009062A (es) | Piperidinil-3-(ariloxi)propanamidas y propanoatos. | |
| NO20061454L (no) | Compounds having CRTH2 antagonist activity | |
| EA200801909A1 (ru) | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина | |
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| MY139058A (en) | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | |
| NO20074781L (no) | 4-Oksokinazolin-3-ylbenzamidderivater for behandling av cytokinsykdommer | |
| TW200602339A (en) | Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists | |
| NO990433L (no) | Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet | |
| MY141736A (en) | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists | |
| MX2021003945A (es) | Compuestos de indolinona para uso como inhibidores de map4k1. | |
| MX2021012904A (es) | Moduladores de la via de respuesta al estres integrada. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| MX2021004280A (es) | Derivados de pirazol como compuestos antagonistas de receptor de histamina h4. | |
| ATE409187T1 (de) | N-(substituierte benzyl)-8-hydroxy-1,6- naphthyridin-7- carbonsäureamide als hiv- integrase-hemmer | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| MX2023009285A (es) | Compuestos novedosos. | |
| EA200400637A1 (ru) | Насыщенные 1-аминоалкилциклогексановые антагонисты nmda, 5-ht3 и нейронных никотиновых рецепторов | |
| HRP20050554B1 (hr) | Supstituirani 1- piperidin-3-il-4-piperidin-4-il-piperazinski derivati i njihova primjena kao neurokininskih antagonista | |
| EP4279138A3 (en) | Crystal of compound as c-met kinase inhibitor and preparation method therefor and use thereof | |
| MX2023005678A (es) | Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas. | |
| JP2007518781A5 (es) | ||
| MX2021016068A (es) | Derivados de isoquinolinona como inhibidores de la proteina quinasa rock y usos del mismo. | |
| MX2021006012A (es) | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. | |
| WO2012087182A3 (ru) | Замещенные метил-амины, антагонисты серотониновых 5-нт6 рецепторов, способы получения и применения |